申请人:Boehringer Mannheim GmbH
公开号:US04288442A1
公开(公告)日:1981-09-08
A piperidinopropyl derivative of the formula ##STR1## in which R.sub.1 and R.sub.2 each independently is hydrogen or a lower alkyl radical, or together are an alkylene radical, R.sub.3 is hydrogen, hydroxy, or acyloxy, R.sub.4 is hydrogen or formyl, A together with the adjacent benzene ring and N-R.sub.4 forms a benzimidazolin-2-one, benzimidazoline-2-thione, oxindole, indazole carbazole, benztriazole, benzimidazole, indoline or indole moiety, and B is a heterocyclic radical or, under certain circumstances, a phenyl radical, either of which is optionally substituted by halogen, hydroxy, lower alkyl, hydroxy-lower alkyl, carboxamido-lower alkyl, lower alkoxy, amino, carboxamido, lower alkyl-carbonylamino, acyl or lower alkylsulphonylamino, or a pharmacologically acceptable salt thereof. The compounds inhibit adrenergic .beta.-receptors and lower blood pressure.
这是一种带有以下结构式的哌啶丙基衍生物:##STR1## 其中R.sub.1和R.sub.2各自独立地为氢或较低的烷基基团,或者一起是一种烷基基团,R.sub.3是氢、羟基或酰氧基,R.sub.4是氢或甲酰基,A与相邻苯环和N-R.sub.4形成苯并咪唑啉-2-酮、苯并咪唑啉-2-硫酮、氧化吲哚、吲哚唑、咔唑、苯并三唑、苯并咪唑、吲哚啉或吲哚基团,B是杂环基团或在某些情况下是苯基基团,任一基团都可以被卤素、羟基、较低的烷基、羟基较低的烷基、羧酰胺较低的烷基、较低的烷氧基、氨基、羧酰胺、较低的烷基-羰基氨基、酰基或较低的烷基磺酰胺基取代,或其药理学上可接受的盐。这些化合物能够抑制肾上腺素能β-受体并降低血压。